Baiyang Pharmaceutical: Signed a "Strategic Cooperation Agreement" with Jikun Pharmaceutical and its actual controlling person.

Baiyang Pharmaceuticals announced on the evening of September 12th that the company has recently signed a "Strategic Cooperation Agreement" with Jikun Pharmaceuticals and its actual controller. The investment party of Baiyang Pharmaceuticals plans to participate in Jikun Pharmaceuticals' current capital increase and share expansion. At the same time, Jikun Pharmaceuticals and its actual controller will actively promote the transfer of some of the company's existing shareholders' equity to the investment party of Baiyang Pharmaceuticals. All parties agree and confirm that after the completion of the Phase II clinical trial for the IPF indication of the JK1033 project held by Jikun Pharmaceuticals, and after the completion of the first subject enrollment in the Phase III clinical trial, the investment party of Baiyang Pharmaceuticals has the right to acquire the "JK1033 project rights" at a reasonable and mutually agreed price. The innovative drug JK1033 project is a small molecule compound extracted from traditional Chinese medicine monomers and their derivatives, selected and optimized through high-throughput screening and reconstruction, intended for the treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.